 |
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Feb 28, 2011
|
23.2 KB |
|
| |
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 1...
|
|
Regeneron Announces March 2011 Investor Conference Presentations
Feb 23, 2011
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Feb. 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Citi 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Tuesday, March 1, 2011RBC Capital Markets' 2011 Healthcare Conference at 10:00 a.m. Eastern Time on Wednesda...
|
|
Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
Feb 22, 2011
|
18.8 KB |
|
| |
TARRYTOWN, N.Y., Feb. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescripti...
|
|
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Feb 17, 2011
|
29.4 KB |
|
| |
TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones.
"2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clini...
|
|
Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
Feb 9, 2011
|
15.7 KB |
|
| |
TARRYTOWN, N.Y., Feb. 9, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will webcast an investor briefing on Sunday, February 13 from 9 a.m. to 10:30 a.m. Eastern Time. At the investor briefing, principal investigators from the VEGF Trap-Eye clinical studies will recap presentations from the Bascom Palm...
|
|
Regeneron Announces Presentation at the ISI Annual Conference
Feb 8, 2011
|
9.1 KB |
|
| |
TARRYTOWN, N.Y., Feb. 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the ISI Annual Conference on Tuesday, February 15, 2011. The presentation is scheduled for 2:10 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations pa...
|
|
Regeneron and Bayer Start Phase 3 Trial to Extend Ophthalmology Research & Development Program for VEGF Trap-Eye in Asia
Jan 18, 2011
|
18.2 KB |
|
| |
TARRYTOWN, N.Y., BERLIN and SINGAPORE, Jan. 18, 2011 /PRNewswire/ -- Regeneron (Nasdaq: REGN) and Bayer HealthCare today announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute (SERI) investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with chor...
|
|
Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
Jan 3, 2011
|
8.7 KB |
|
| |
TARRYTOWN, N.Y., Jan. 3, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011. The presentation is scheduled for 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). The session may be accessed through the Company's web site, ...
|
|
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Dec 20, 2010
|
131.2 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due ...
|
|
Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Dec 20, 2010
|
9.1 KB |
|
| |
TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow...
|
|
Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
Dec 6, 2010
|
8.6 KB |
|
| |
TARRYTOWN, N.Y., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 2010 Deutsche Bank BioFest on Tuesday, December 14, 2010. The presentation is scheduled for 8:00 a.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Invest...
|
|
Regeneron Announces Presentation at the 22nd Annual Piper Jaffray Healthcare Conference
Nov 23, 2010
|
8.6 KB |
|
| |
TARRYTOWN, N.Y., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 22nd Annual Piper Jaffray Healthcare Conference on Tuesday, November 30, 2010. The presentation is scheduled for 12:00 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regen...
|
|
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
Nov 22, 2010
|
21.8 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including V...
|
|
Regeneron Schedules November 22, 2010 Teleconference and Webcast to Discuss Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
Nov 19, 2010
|
9.1 KB |
|
| |
TARRYTOWN, N.Y., Nov. 19, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, November 22, to discuss results of two Phase 3 studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration, VIEW 1 and VIEW 2, and its VEGF...
|
|
Christine A. Poon Elected to Regeneron Board of Directors
Nov 15, 2010
|
11.7 KB |
|
| |
TARRYTOWN, N.Y., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has elected Christine A. Poon to fill a new seat on its expanded Board of Directors. Ms. Poon currently serves as dean of Ohio State University's Fisher College of Business. She was formerly Vice Chairman of the Board of...
|
|
Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
Nov 2, 2010
|
8.5 KB |
|
| |
TARRYTOWN, N.Y., Nov. 2, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 2010 Credit Suisse Annual Healthcare Conference on Wednesday, November 10, 2010. The presentation is scheduled for 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time). The session may be accessed ...
|
|
Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights
Oct 28, 2010
|
21.3 KB |
|
| |
TARRYTOWN, N.Y., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2010 and provided current business highlights.
Current Business Highlights
Public Offering of Common Stock
In October 2010, the Company completed a public offering of 6,32...
|
|
Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
Oct 15, 2010
|
8.5 KB |
|
| |
TARRYTOWN, N.Y., Oct 15, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010. The presentation is scheduled for 9:00 a.m. Eastern Time. The session may be accessed through the Company's...
|
|
Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
Oct 13, 2010
|
10.3 KB |
|
| |
NEW YORK, Oct 13, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today the completion of its previously announced underwritten public offering of 5,500,000 shares of Common Stock, as well as 825,000 additional shares of its Common Stock pursuant to the full exercise of the over-allotment option...
|
|
Regeneron Increases Size of Public Offering of Common Stock
Oct 8, 2010
|
10.2 KB |
|
| |
NEW YORK, Oct 08, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has increased the size of its previously announced underwritten public offering of Common Stock from 4,500,000 shares to 5,500,000 shares and agreed to an indicative price of $28.00 per share for the offering. Citi i...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds